Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.460
+0.070 (2.06%)
At close: May 19, 2026, 4:00 PM EDT
3.490
+0.030 (0.87%)
After-hours: May 19, 2026, 7:45 PM EDT
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Iovance Biotherapeutics stock have a consensus rating of "Buy" and an average price target of $8.80, which forecasts a 154.34% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $14.
Price Target: $8.80 (+154.34%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 2 |
| Buy | 5 | 5 | 6 | 5 | 5 | 3 |
| Hold | 3 | 3 | 3 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 10 | 10 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $16 → $14 | Strong Buy | Maintains | $16 → $14 | +304.62% | May 7, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +362.43% | Apr 10, 2026 |
| UBS | UBS | Hold Maintains $2 → $4 | Hold | Maintains | $2 → $4 | +15.61% | Mar 5, 2026 |
| Citizens | Citizens | Hold → Buy Upgrades $5 | Hold → Buy | Upgrades | $5 | +44.51% | Mar 3, 2026 |
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | +217.92% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
377.89M
from 263.50M
Increased by 43.41%
Revenue Next Year
528.74M
from 377.89M
Increased by 39.92%
EPS This Year
-0.53
from -1.09
EPS Next Year
-0.25
from -0.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 437.5M | 732.8M | ||||||
| Avg | 377.9M | 528.7M | ||||||
| Low | 322.8M | 431.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 66.0% | 93.9% | ||||||
| Avg | 43.4% | 39.9% | ||||||
| Low | 22.5% | 14.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.28 | -0.04 | ||||||
| Avg | -0.53 | -0.25 | ||||||
| Low | -0.75 | -0.56 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.